Novavax is trading at $8.15 (+5.84%) in pre-market as investors position ahead of its August 06, 2026 earnings report.
- Analysts expect Q2 2026 revenue of $52.06 million and an EPS loss of $0.38.
- Shares have been trading near $7.46, significantly below the average price target of $13.00.
- The price action appears tied to pre-earnings anticipation rather than broader market direction.